FindTrial
Sign In

Study for correlation between changes in stimulatory immune checkpoints of peripheral blood lymphocyte and efficacy before and after treatment with PD-1 for advanced NSCLC patients

Study for correlation between changes in stimulatory immune checkpoints of peripheral blood lymphocyte and efficacy before and after treatment with PD-1 for advanced NSCLC patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR1900002416
Enrollment
Unknown
Registered
2019-06-23
Start date
2019-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Disease progression group:Syndilumab combined with chemotherapy
Disease controlled group:Syndilumab combined with chemotherapy

Sponsors

Shanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged greater than or equal to 18 years; 2. Histopathology is clearly diagnosed as NSCLC; 3. Clinical stage is stage IV; 4. ECOG score is 0 to 2 points; 5. There are evaluable lesions.

Exclusion criteria

Exclusion criteria: 1. There have been acute cardiogenic diseases or chronic basic diseases, which may interfere with treatment after evaluation; 2. previous severe liver and kidney dysfunction; 3. end stage, inability to tolerate PD-1 treatment; 4. patients autoimmune system disease.

Design outcomes

Primary

MeasureTime frame
Peripheral blood CTLA-4, PD1, TIM-3, LAG-3;—

Countries

China

Contacts

Public ContactLiu Likun

Shanxi Provincial Hospital of Traditional Chinese Medicine

LIkun133@126.com+86 13623609166

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026